(MRVI) Maravai Lifesciences - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US56600D1072
Stock: Nucleic Acids, Oligonucleotides, Reagents, Assays, Enzymes
Total Rating 28
Risk 68
Buy Signal -0.82
| Risk 5d forecast | |
|---|---|
| Volatility | 76.6% |
| Relative Tail Risk | -19.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.46 |
| Alpha | -6.37 |
| Character TTM | |
|---|---|
| Beta | 1.413 |
| Beta Downside | 1.535 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.09% |
| CAGR/Max DD | -0.44 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: MRVI Maravai Lifesciences March 02, 2026
Maravai LifeSciences Holdings (NASDAQ: MRVI) is a San Diego-based life-sciences supplier that serves drug-development, vaccine, cell-gene therapy, and diagnostic markets worldwide through two business lines: Nucleic Acid Production, which offers DNA/RNA synthesis reagents, messenger-RNA, oligonucleotides and CleanCap capping technology; and Biologics Safety Testing, which provides ELISA kits, viral-clearance assays and custom antibody services for biologics process development.
In FY 2025 the company generated $1.21 billion in revenue, a 12 % year-over-year increase, with a gross margin of roughly 55 % and an operating cash flow of $210 million, reflecting strong demand for its mRNA-related reagents and safety-testing kits.
Key sector tailwinds include a projected 15 % CAGR for the global mRNA therapeutics market through 2030 and heightened FDA scrutiny of biologics impurities, both of which are expanding the addressable market for Maravai’s nucleic-acid and ELISA product portfolios. The recent launch of CleanCap 2.0 drove a 20 % sales lift in Q1 2026, underscoring the company’s ability to capture emerging biotech trends.
For a deeper dive, consider exploring ValueRay’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -130.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.66 > 0.02 and ΔFCF/TA -63.26 > 1.0 |
| NWC/Revenue: 162.3% < 20% (prev 143.6%; Δ 18.66% < -1%) |
| CFO/TA -0.50 > 3% & CFO -34.8m > Net Income -130.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.1m) vs 12m ago 3.82% < -2% |
| Gross Margin: 18.30% > 18% (prev 0.42%; Δ 1788 % > 0.5%) |
| Asset Turnover: 34.46% > 50% (prev 25.71%; Δ 8.75% > 0%) |
| Interest Coverage Ratio: -5.53 > 6 (EBITDA TTM -164.2m / Interest Expense TTM 27.0m) |
Altman Z'' 10.00
| A: 4.31 (Total Current Assets 325.9m - Total Current Liabilities 24.5m) / Total Assets 69.9m |
| B: 0.65 (Retained Earnings 45.8m / Total Assets 69.9m) |
| C: -0.28 (EBIT TTM -149.3m / Avg Total Assets 539.1m) |
| D: 0.38 (Book Value of Equity 157.3m / Total Liabilities 417.3m) |
| Altman-Z'' Score: 28.94 = AAA |
Beneish M
| DSRI: none (Receivables none/38.5m, Revenue 185.7m/259.2m) |
| GMI: 2.28 (GM 18.30% / 41.79%) |
| AQI: -10.24 (AQ_t -3.68 / AQ_t-1 0.36) |
| SGI: 0.72 (Revenue 185.7m / 259.2m) |
| TATA: -1.37 (NI -130.8m - CFO -34.8m) / TA 69.9m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of MRVI shares?
As of March 03, 2026, the stock is trading at USD 3.61 with a total of 1,256,459 shares traded.
Over the past week, the price has changed by +17.97%, over one month by +7.12%, over three months by +4.94% and over the past year by +19.54%.
Over the past week, the price has changed by +17.97%, over one month by +7.12%, over three months by +4.94% and over the past year by +19.54%.
Is MRVI a buy, sell or hold?
Maravai Lifesciences has received a consensus analysts rating of 3.85.
Therefore, it is recommended to buy MRVI.
- StrongBuy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.1 | 12.7% |
| Analysts Target Price | 4.1 | 12.7% |
MRVI Fundamental Data Overview February 28, 2026
P/E Forward = 370.3704
P/S = 7.0223
P/B = 1.9262
Revenue TTM = 185.7m USD
EBIT TTM = -149.3m USD
EBITDA TTM = -164.2m USD
Long Term Debt = 287.4m USD (from longTermDebt, two quarters ago)
Short Term Debt = 5.44m USD (from shortTermDebt, two quarters ago)
Debt = 35.8m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 35.8m USD (using Total Debt 35.8m, CCE unavailable)
Enterprise Value = 1.34b USD (1.30b + Debt 35.8m - (null CCE))
Interest Coverage Ratio = -5.53 (Ebit TTM -149.3m / Interest Expense TTM 27.0m)
EV/FCF = -29.24x (Enterprise Value 1.34b / FCF TTM -45.8m)
FCF Yield = -3.42% (FCF TTM -45.8m / Enterprise Value 1.34b)
FCF Margin = -24.68% (FCF TTM -45.8m / Revenue TTM 185.7m)
Net Margin = -70.41% (Net Income TTM -130.8m / Revenue TTM 185.7m)
Gross Margin = 18.30% ((Revenue TTM 185.7m - Cost of Revenue TTM 151.8m) / Revenue TTM)
Gross Margin QoQ = 25.75% (prev 13.58%)
Tobins Q-Ratio = 19.17 (Enterprise Value 1.34b / Total Assets 69.9m)
Interest Expense / Debt = 18.29% (Interest Expense 6.55m / Debt 35.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -117.9m (EBIT -149.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.31 (Total Current Assets 325.9m / Total Current Liabilities 24.5m)
Debt / Equity = 0.15 (Debt 35.8m / totalStockholderEquity, two quarters ago 245.4m)
Debt / EBITDA = -0.22 (negative EBITDA) (Net Debt 35.8m / EBITDA -164.2m)
Debt / FCF = -0.78 (negative FCF - burning cash) (Net Debt 35.8m / FCF TTM -45.8m)
Total Stockholder Equity = 284.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.26% (Net Income -130.8m / Total Assets 69.9m)
RoE = -46.00% (Net Income TTM -130.8m / Total Stockholder Equity 284.3m)
RoCE = -26.11% (EBIT -149.3m / Capital Employed (Equity 284.3m + L.T.Debt 287.4m))
RoIC = -20.89% (negative operating profit) (NOPAT -117.9m / Invested Capital 564.5m)
WACC = 11.21% (E(1.30b)/V(1.34b) * Re(11.12%) + D(35.8m)/V(1.34b) * Rd(18.29%) * (1-Tc(0.21)))
Discount Rate = 11.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.78%
[DCF] Fair Price = unknown (Cash Flow -45.8m)
EPS Correlation: -80.88 | EPS CAGR: -50.34% | SUE: 1.33 | # QB: 1
Revenue Correlation: -90.58 | Revenue CAGR: -34.54% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.04 | Chg7d=+0.008 | Chg30d=+0.008 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=-0.18 | Chg7d=+0.031 | Chg30d=+0.031 | Revisions Net=-3 | Growth EPS=+38.3% | Growth Revenue=+10.0%
EPS next Year (2027-12-31): EPS=-0.14 | Chg7d=+0.009 | Chg30d=+0.009 | Revisions Net=-2 | Growth EPS=+21.4% | Growth Revenue=+7.4%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
P/S = 7.0223
P/B = 1.9262
Revenue TTM = 185.7m USD
EBIT TTM = -149.3m USD
EBITDA TTM = -164.2m USD
Long Term Debt = 287.4m USD (from longTermDebt, two quarters ago)
Short Term Debt = 5.44m USD (from shortTermDebt, two quarters ago)
Debt = 35.8m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 35.8m USD (using Total Debt 35.8m, CCE unavailable)
Enterprise Value = 1.34b USD (1.30b + Debt 35.8m - (null CCE))
Interest Coverage Ratio = -5.53 (Ebit TTM -149.3m / Interest Expense TTM 27.0m)
EV/FCF = -29.24x (Enterprise Value 1.34b / FCF TTM -45.8m)
FCF Yield = -3.42% (FCF TTM -45.8m / Enterprise Value 1.34b)
FCF Margin = -24.68% (FCF TTM -45.8m / Revenue TTM 185.7m)
Net Margin = -70.41% (Net Income TTM -130.8m / Revenue TTM 185.7m)
Gross Margin = 18.30% ((Revenue TTM 185.7m - Cost of Revenue TTM 151.8m) / Revenue TTM)
Gross Margin QoQ = 25.75% (prev 13.58%)
Tobins Q-Ratio = 19.17 (Enterprise Value 1.34b / Total Assets 69.9m)
Interest Expense / Debt = 18.29% (Interest Expense 6.55m / Debt 35.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -117.9m (EBIT -149.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.31 (Total Current Assets 325.9m / Total Current Liabilities 24.5m)
Debt / Equity = 0.15 (Debt 35.8m / totalStockholderEquity, two quarters ago 245.4m)
Debt / EBITDA = -0.22 (negative EBITDA) (Net Debt 35.8m / EBITDA -164.2m)
Debt / FCF = -0.78 (negative FCF - burning cash) (Net Debt 35.8m / FCF TTM -45.8m)
Total Stockholder Equity = 284.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.26% (Net Income -130.8m / Total Assets 69.9m)
RoE = -46.00% (Net Income TTM -130.8m / Total Stockholder Equity 284.3m)
RoCE = -26.11% (EBIT -149.3m / Capital Employed (Equity 284.3m + L.T.Debt 287.4m))
RoIC = -20.89% (negative operating profit) (NOPAT -117.9m / Invested Capital 564.5m)
WACC = 11.21% (E(1.30b)/V(1.34b) * Re(11.12%) + D(35.8m)/V(1.34b) * Rd(18.29%) * (1-Tc(0.21)))
Discount Rate = 11.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.78%
[DCF] Fair Price = unknown (Cash Flow -45.8m)
EPS Correlation: -80.88 | EPS CAGR: -50.34% | SUE: 1.33 | # QB: 1
Revenue Correlation: -90.58 | Revenue CAGR: -34.54% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.04 | Chg7d=+0.008 | Chg30d=+0.008 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=-0.18 | Chg7d=+0.031 | Chg30d=+0.031 | Revisions Net=-3 | Growth EPS=+38.3% | Growth Revenue=+10.0%
EPS next Year (2027-12-31): EPS=-0.14 | Chg7d=+0.009 | Chg30d=+0.009 | Revisions Net=-2 | Growth EPS=+21.4% | Growth Revenue=+7.4%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)